Oncolytic Immunotherapies For Cancer
Oncolytic Immunotherapies For Cancer
Oncolytic Immunotherapies For Cancer
Oncolytic Immunotherapies For Cancer
Adze Biotechnology is developing a platform of oncolytic immunotherapies with 12+ assets against over 15 indications.
Each asset is designed to enhance or carry checkpoint inhibitors.
Our goal is to treat tumors directly while recruiting and amplifying the patient's immune response to fight cancers.
Adze oncolytic immunotherapy payloads target immune stimulatory and inhibitory receptors on T, NK, and dendritic cells and macrophages to further amplify the immune response.
The neoantigens released from lysed cancer cells, coupled with recruited and stimulated immune cells, generate in situ systemic cancer vaccine responses, a key goal in immuno-oncology.
Adze oncolytic immunotherapies also carry their own unique PD-L1 blocking and retargeting payloads.
Copyright © 2021 Adze Biotechnology - All Rights Reserved.